BioBusiness

Investors are lining up for the biosimilars market as patents reach expiration and regulatory pathways are defined.

Manufacturers are under pressure to develop pipelines, promote quality, and justify pricing.

Although competing therapies will continue to be released in the immune-oncology space, efficacy profiles, combination regimens, and administration setting may influence a drug’s preferred status more than price.

Pharmacy benefit manager Express Scripts offers Viekira Pak at a discount and excludes the drug’s higher-priced competitors from its formulary.

On December 8, Pfizer announced that it will establish a research program in gene therapy, and collaborate with Spark Therapeutics in Philadelphia, to develop potential gene therapy treatments for hemophilia.

Enhanced R&D efforts and the growing manufacture of finished-dosage drugs in India will shape the country's future success, according to a new report from CPhI.

Japanese drugmaker Otsuka announced plans to buy CNS-specialist Avanir Pharmaceuticals for $3.5 billion in an all-cash tender offer.

Biopharma employees report gains in compensation and job satisfaction, as industry growth continues.

Biotech drug manufacturers' emails may have been hacked by individuals with sophisticated investment banking skills, according to a report from the New York Times.

Merck announced an agreement with NewLink Genetics to acquire exclusive rights to its experimental Ebola vaccine, rVSV-EBOV, for $50 million.

Despite recent changes in corporate tax law, Ireland remains a valuable and attractive partner in the development and manufacture of biopharmaceuticals.

Approximately 40% of total global growth will come from specialty medications, according to a new report from the IMS Institute for Healthcare Informatics.

Biopharma continues to adopt single-use technologies, but also seeks more innovation and improvements in products.

Dual sourcing is one of many possible solutions to securing the supply chain.

M&A transactions accounted for nearly $15 billion more this year than for the same period a year ago.

The authors take a look at some of the recent developments in the German pharmaceutical market.

The authors take a look at the past and future impact of the Indian Pharmacopoeia Commission.

AAPS supports graduate-level programs impacted by cutbacks in funding and resources.

GSK is found guilty of offering bribes to doctors and is fined $489 million.

A dynamic market, industry consolidation, and demand fluctuations lead to a mixed picture of pricing results.

Trends in real estate and facility clusters give insight into the state of the biopharmaceutical industry.

Chinese healthcare reforms may be a double-edged sword for foreign companies.

Data analytic strategies can help companies capitalize on personalized medicine.

New International Council on Biotechnology Associations advocates biotechnology growth.

Gene therapy, immune-oncology, and digital healthcare technologies offer investors promise for innovation investments.